| abstract |
The present invention relates to a novel heterocyclic compound of formula (I) wherein Y is a group of formula (2), R15-C (R14) = N-O-, wherein R1 is hydrogen or (C1-C6) -alkyl; R2 is hydrogen, -CO-C- (R4) = C- (R4) -R5, wherein R4 is hydrogen or C1-C4 alkyl, and R5 is C4-C8 alkyl, C2-C8 alkenyl, and the like, Y represents the following group wherein X is O or S, R7 is the same as R4, R8 is R10-C- (R9) = C- (R9) -, where R9 is the same as R4, R10 is 3-6 C 1 -C 5 alkyl and the like, Y- (CH 2) nO- is attached at the 6 or 7 position to the tetrahydroisoquinoline backbone; and n is an integer from 1 to 4, or a pharmaceutically acceptable salt thereof. A pharmaceutically acceptable salt of a compound of formula (I) of the present invention and a blood glucose lowering agent, a blood lipid lowering agent, an insulin resistance enhancer, an antidiabetic agent, an anti-diabetic agent, an anti-diabetic agent, , an anti-inflammatory agent, an agent for the prevention or treatment of diseases mediated by PPAR, and an agent for the prevention or treatment of syndrome X. HE |